作者:Andrew Whyte、Katherine I. Burton、Jingli Zhang、Mark Lautens
DOI:10.1002/anie.201808460
日期:2018.10.15
An enantioselective copper‐catalyzed intramolecular borylacylation is reported. The reaction proceeds through an initial enantioselective borylcupration of the styrene, followed by a nucleophilic attack on the tethered carbamoyl chloride. The products, chiral borylated 3,3‐disubstituted oxindoles, were generated in excellent yields and enantioselectivities. The versatile carbon–boron bond provides
3-amidoindolyl derivatives and pharmaceutical compositions thereof
申请人:Merrell Dow Pharmaceuticals Inc.
公开号:US05189054A1
公开(公告)日:1993-02-23
The present invention is directed to a new class of 3-amido and 3-sulfamido-indolyl NMDA antagonists and their use in the treatment of a number of disease states.
Rhodium(III)-Catalyzed Direct Cyanation of Aromatic C–H Bond to Form 2-(Alkylamino)benzonitriles Using <i>N</i>-Nitroso As Directing Group
作者:Jiawei Dong、Zhongjie Wu、Zhengyi Liu、Ping Liu、Peipei Sun
DOI:10.1021/acs.joc.5b01666
日期:2015.12.18
2-(Alkylamino)benzonitriles were synthesized via a rhodium-catalyzed cyanation on the aryl C–H bond and subsequent denitrosation of N-nitrosoarylamines using a removable nitroso as the directing group, in which N-cyano-N-phenyl-p-methylbenzenesulfonamide (NCTS) was used as the “CN” source. Various substituents on the aryl ring and amino group of N-nitrosoarylamines tolerated the reaction, and the corresponding
The present invention provides compounds of formula I
and pharmaceutically acceptable salts thereof.
The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
The present invention provides a heterocyclic compound represented by the following formula (I), wherein X
A
represents CH and the like, R
1
represents cycloalkyl optionally having substituent(s) and the like, L represents a bond and the like, Y
A
represents —NH— and the like, R
2
represents a hydrogen atom and the like, R
3A
represents the following formula (R
3A
-1) (wherein, R
3
represents hydroxy and the like) and the like, and R
4A
represents the following formula (R
4A
-1) (wherein, R
4
and R
5
are the same or different and each represents a hydrogen atom and the like) and the like, or a pharmaceutically acceptable salt thereof, which is useful as a prophylactic and/or therapeutic agent for skin diseases and the like, and the like.